 Shanta Zimmer
Concepts (290)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 13 | 2021 | 554 | 1.310 |
Why?
| | Influenza A Virus, H1N1 Subtype | 8 | 2011 | 140 | 1.090 |
Why?
| | Physician-Patient Relations | 3 | 2016 | 490 | 0.800 |
Why?
| | Physicians, Women | 1 | 2020 | 53 | 0.730 |
Why?
| | Vulnerable Populations | 1 | 2020 | 147 | 0.680 |
Why?
| | Communicable Diseases | 1 | 2020 | 132 | 0.660 |
Why?
| | Coronavirus Infections | 2 | 2023 | 339 | 0.660 |
Why?
| | Neisseria meningitidis | 3 | 2007 | 19 | 0.650 |
Why?
| | Lymphocyte Antigen 96 | 3 | 2008 | 24 | 0.650 |
Why?
| | Internship and Residency | 6 | 2019 | 1001 | 0.610 |
Why?
| | Professional Misconduct | 1 | 2016 | 11 | 0.550 |
Why?
| | Pennsylvania | 8 | 2021 | 101 | 0.540 |
Why?
| | Meningitis, Meningococcal | 2 | 2006 | 5 | 0.540 |
Why?
| | Faculty | 1 | 2016 | 135 | 0.520 |
Why?
| | Meningococcal Vaccines | 2 | 2006 | 49 | 0.510 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 348 | 0.510 |
Why?
| | Internal Medicine | 4 | 2018 | 215 | 0.490 |
Why?
| | Curriculum | 3 | 2019 | 910 | 0.480 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 146 | 0.410 |
Why?
| | Influenza Vaccines | 6 | 2011 | 500 | 0.410 |
Why?
| | Physicians | 3 | 2016 | 794 | 0.400 |
Why?
| | Education, Medical, Graduate | 4 | 2019 | 399 | 0.380 |
Why?
| | Computer Simulation | 9 | 2012 | 922 | 0.360 |
Why?
| | Reassortant Viruses | 1 | 2009 | 7 | 0.350 |
Why?
| | Zoonoses | 1 | 2009 | 20 | 0.350 |
Why?
| | Education, Medical, Undergraduate | 1 | 2012 | 199 | 0.350 |
Why?
| | Communicable Diseases, Emerging | 1 | 2009 | 28 | 0.340 |
Why?
| | Orthomyxoviridae Infections | 1 | 2009 | 53 | 0.340 |
Why?
| | Toll-Like Receptor 4 | 4 | 2008 | 330 | 0.340 |
Why?
| | Lipid A | 3 | 2007 | 28 | 0.330 |
Why?
| | Respiratory Tract Infections | 2 | 2023 | 331 | 0.320 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 137 | 0.320 |
Why?
| | Students, Medical | 1 | 2012 | 311 | 0.310 |
Why?
| | Zygomycosis | 1 | 2007 | 6 | 0.300 |
Why?
| | Cyclosporiasis | 1 | 2007 | 1 | 0.300 |
Why?
| | Paclitaxel | 1 | 2008 | 195 | 0.300 |
Why?
| | Dermatomycoses | 1 | 2007 | 9 | 0.300 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2008 | 180 | 0.300 |
Why?
| | Oxazolidinones | 2 | 2004 | 14 | 0.300 |
Why?
| | Acetamides | 2 | 2004 | 26 | 0.290 |
Why?
| | Leadership | 2 | 2020 | 311 | 0.290 |
Why?
| | Thiazoles | 1 | 2007 | 121 | 0.280 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2005 | 67 | 0.280 |
Why?
| | Humans | 49 | 2023 | 118974 | 0.280 |
Why?
| | Fungi | 1 | 2007 | 123 | 0.270 |
Why?
| | Triazoles | 1 | 2007 | 134 | 0.270 |
Why?
| | Drug Hypersensitivity | 1 | 2007 | 83 | 0.270 |
Why?
| | History, 21st Century | 2 | 2020 | 170 | 0.260 |
Why?
| | Disease Outbreaks | 5 | 2010 | 322 | 0.260 |
Why?
| | Schools | 4 | 2021 | 411 | 0.260 |
Why?
| | History, 20th Century | 2 | 2020 | 281 | 0.250 |
Why?
| | Medical Tourism | 1 | 2023 | 10 | 0.230 |
Why?
| | Sulfonamides | 1 | 2007 | 445 | 0.230 |
Why?
| | Coronavirus 229E, Human | 1 | 2023 | 4 | 0.230 |
Why?
| | Coronavirus NL63, Human | 1 | 2023 | 3 | 0.230 |
Why?
| | Coronavirus OC43, Human | 1 | 2023 | 5 | 0.230 |
Why?
| | Enterococcus faecalis | 1 | 2003 | 24 | 0.230 |
Why?
| | Models, Molecular | 1 | 2008 | 1435 | 0.230 |
Why?
| | Endocarditis, Bacterial | 1 | 2003 | 37 | 0.230 |
Why?
| | Meningitis | 1 | 2023 | 74 | 0.210 |
Why?
| | Models, Economic | 3 | 2012 | 48 | 0.210 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2022 | 174 | 0.210 |
Why?
| | Viruses | 1 | 2023 | 96 | 0.210 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 97 | 0.200 |
Why?
| | Emergency Responders | 1 | 2021 | 34 | 0.190 |
Why?
| | Program Evaluation | 3 | 2019 | 845 | 0.190 |
Why?
| | Crowding | 1 | 2020 | 38 | 0.180 |
Why?
| | Awards and Prizes | 1 | 2020 | 57 | 0.180 |
Why?
| | Shoulder | 1 | 2020 | 94 | 0.170 |
Why?
| | Frail Elderly | 1 | 2020 | 107 | 0.170 |
Why?
| | Adult | 18 | 2023 | 31512 | 0.170 |
Why?
| | Prisons | 1 | 2020 | 74 | 0.170 |
Why?
| | Nursing Homes | 1 | 2020 | 130 | 0.170 |
Why?
| | Minority Groups | 1 | 2020 | 237 | 0.170 |
Why?
| | Virus Diseases | 1 | 2021 | 198 | 0.160 |
Why?
| | Surgery Department, Hospital | 1 | 2018 | 21 | 0.160 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 334 | 0.160 |
Why?
| | Financing, Organized | 1 | 2018 | 34 | 0.160 |
Why?
| | Faculty, Medical | 2 | 2018 | 252 | 0.160 |
Why?
| | Anesthesiology | 1 | 2018 | 39 | 0.160 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 115 | 0.160 |
Why?
| | Point-of-Care Systems | 2 | 2017 | 151 | 0.160 |
Why?
| | Urban Population | 1 | 2020 | 409 | 0.150 |
Why?
| | Preceptorship | 1 | 2017 | 63 | 0.150 |
Why?
| | Occupational Exposure | 1 | 2020 | 277 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.150 |
Why?
| | Population Surveillance | 2 | 2011 | 413 | 0.150 |
Why?
| | Rural Population | 1 | 2020 | 452 | 0.140 |
Why?
| | Female | 18 | 2022 | 61565 | 0.140 |
Why?
| | Societies, Medical | 1 | 2020 | 703 | 0.140 |
Why?
| | HIV Infections | 2 | 2022 | 2459 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 250 | 0.140 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 664 | 0.130 |
Why?
| | United States | 7 | 2020 | 12555 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 265 | 0.130 |
Why?
| | Endotoxins | 2 | 2007 | 234 | 0.130 |
Why?
| | Sexual Behavior | 1 | 2019 | 437 | 0.130 |
Why?
| | Antiviral Agents | 2 | 2011 | 654 | 0.130 |
Why?
| | Cardiology | 1 | 2017 | 272 | 0.130 |
Why?
| | Male | 17 | 2022 | 57801 | 0.130 |
Why?
| | Binding Sites | 2 | 2008 | 1224 | 0.120 |
Why?
| | Recombinant Proteins | 2 | 2008 | 1308 | 0.120 |
Why?
| | Clinical Competence | 2 | 2018 | 951 | 0.120 |
Why?
| | Anti-Bacterial Agents | 1 | 2003 | 1510 | 0.120 |
Why?
| | Work Schedule Tolerance | 1 | 2013 | 36 | 0.120 |
Why?
| | Hand Hygiene | 1 | 2013 | 7 | 0.120 |
Why?
| | Macrophage Activation | 2 | 2005 | 168 | 0.120 |
Why?
| | Macrophages | 4 | 2008 | 1324 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 693 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2013 | 81 | 0.110 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 4708 | 0.110 |
Why?
| | Receptors, Cell Surface | 2 | 2005 | 367 | 0.110 |
Why?
| | Aged | 8 | 2020 | 19657 | 0.110 |
Why?
| | Social Support | 1 | 2016 | 542 | 0.110 |
Why?
| | Antibodies, Viral | 2 | 2021 | 542 | 0.110 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 446 | 0.110 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2011 | 2062 | 0.100 |
Why?
| | Patient Admission | 1 | 2013 | 176 | 0.100 |
Why?
| | Patients | 1 | 2013 | 175 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1355 | 0.100 |
Why?
| | Hospitalization | 1 | 2020 | 1785 | 0.100 |
Why?
| | Poverty Areas | 1 | 2011 | 35 | 0.100 |
Why?
| | Quality Improvement | 1 | 2019 | 963 | 0.100 |
Why?
| | Patient Preference | 1 | 2013 | 170 | 0.100 |
Why?
| | Cyclopentanes | 1 | 2011 | 16 | 0.100 |
Why?
| | Guanidines | 1 | 2011 | 37 | 0.100 |
Why?
| | Students | 1 | 2016 | 509 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2011 | 2275 | 0.100 |
Why?
| | Health Care Costs | 2 | 2011 | 394 | 0.100 |
Why?
| | Hemagglutinins | 1 | 2010 | 11 | 0.100 |
Why?
| | Clostridium Infections | 1 | 2011 | 57 | 0.100 |
Why?
| | Pneumococcal Infections | 1 | 2011 | 96 | 0.090 |
Why?
| | Communication | 1 | 2016 | 761 | 0.090 |
Why?
| | Health Care Rationing | 1 | 2010 | 48 | 0.090 |
Why?
| | Young Adult | 7 | 2020 | 10793 | 0.090 |
Why?
| | Quarantine | 1 | 2010 | 25 | 0.090 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 346 | 0.090 |
Why?
| | Seasons | 2 | 2023 | 461 | 0.090 |
Why?
| | Occupational Health Services | 1 | 2009 | 31 | 0.090 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 190 | 0.090 |
Why?
| | Influenza A Virus, H2N2 Subtype | 1 | 2009 | 1 | 0.090 |
Why?
| | Antigenic Variation | 1 | 2009 | 9 | 0.090 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 207 | 0.090 |
Why?
| | Antibody Specificity | 1 | 2009 | 184 | 0.090 |
Why?
| | Cross Infection | 1 | 2011 | 205 | 0.080 |
Why?
| | Child | 9 | 2023 | 19129 | 0.080 |
Why?
| | Birds | 1 | 2009 | 81 | 0.080 |
Why?
| | Child, Preschool | 7 | 2021 | 9491 | 0.080 |
Why?
| | Genome, Viral | 1 | 2009 | 124 | 0.080 |
Why?
| | Primary Prevention | 1 | 2010 | 185 | 0.080 |
Why?
| | Disease Management | 1 | 2012 | 571 | 0.080 |
Why?
| | Meningitis, Bacterial | 1 | 2008 | 51 | 0.080 |
Why?
| | Carbohydrate Conformation | 1 | 2007 | 15 | 0.080 |
Why?
| | Pichia | 1 | 2007 | 20 | 0.080 |
Why?
| | Tubulin | 1 | 2008 | 122 | 0.080 |
Why?
| | Asthma | 1 | 2020 | 2158 | 0.080 |
Why?
| | Protein Structure, Secondary | 1 | 2008 | 338 | 0.080 |
Why?
| | Cyclospora | 1 | 2007 | 1 | 0.080 |
Why?
| | Antiparasitic Agents | 1 | 2007 | 3 | 0.080 |
Why?
| | Nitro Compounds | 1 | 2007 | 6 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2011 | 378 | 0.070 |
Why?
| | Cell Line | 3 | 2008 | 2707 | 0.070 |
Why?
| | Linezolid | 2 | 2004 | 16 | 0.070 |
Why?
| | Surface Properties | 1 | 2008 | 397 | 0.070 |
Why?
| | Species Specificity | 1 | 2008 | 565 | 0.070 |
Why?
| | Neonatal Screening | 1 | 2008 | 152 | 0.070 |
Why?
| | District of Columbia | 3 | 2011 | 27 | 0.070 |
Why?
| | Swine | 1 | 2009 | 730 | 0.070 |
Why?
| | Phylogeny | 1 | 2010 | 816 | 0.070 |
Why?
| | Adolescent | 7 | 2022 | 18480 | 0.070 |
Why?
| | Chronic Disease | 1 | 2012 | 1636 | 0.070 |
Why?
| | Antifungal Agents | 1 | 2007 | 134 | 0.070 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 823 | 0.070 |
Why?
| | Vancomycin Resistance | 1 | 2005 | 15 | 0.070 |
Why?
| | Enterococcus | 1 | 2005 | 18 | 0.070 |
Why?
| | Evolution, Molecular | 1 | 2009 | 454 | 0.070 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 79 | 0.070 |
Why?
| | Middle Aged | 9 | 2021 | 27617 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2011 | 781 | 0.060 |
Why?
| | Transfection | 1 | 2007 | 888 | 0.060 |
Why?
| | Efficiency | 2 | 2019 | 89 | 0.060 |
Why?
| | Receptors, Immunologic | 1 | 2005 | 209 | 0.060 |
Why?
| | Vaccines, Conjugate | 1 | 2004 | 63 | 0.060 |
Why?
| | Animals | 5 | 2009 | 33381 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 1945 | 0.060 |
Why?
| | Lipopolysaccharides | 2 | 2005 | 870 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2020 | 6561 | 0.060 |
Why?
| | Bacteremia | 1 | 2005 | 161 | 0.060 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2004 | 88 | 0.060 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2004 | 122 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1171 | 0.060 |
Why?
| | Protein Binding | 1 | 2008 | 1975 | 0.050 |
Why?
| | Models, Statistical | 3 | 2011 | 636 | 0.050 |
Why?
| | Odds Ratio | 2 | 2021 | 996 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2871 | 0.050 |
Why?
| | Infant | 4 | 2012 | 8293 | 0.050 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 227 | 0.050 |
Why?
| | Influenza B virus | 1 | 2021 | 33 | 0.050 |
Why?
| | Contact Tracing | 1 | 2021 | 16 | 0.050 |
Why?
| | Absenteeism | 1 | 2021 | 38 | 0.050 |
Why?
| | Monte Carlo Method | 2 | 2011 | 146 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2022 | 166 | 0.050 |
Why?
| | Risk Factors | 3 | 2021 | 9000 | 0.050 |
Why?
| | Membrane Cofactor Protein | 2 | 2011 | 12 | 0.050 |
Why?
| | Ecology | 1 | 2021 | 104 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2007 | 4077 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 559 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2007 | 942 | 0.040 |
Why?
| | Temperature | 1 | 2021 | 622 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 226 | 0.040 |
Why?
| | Cost-Benefit Analysis | 2 | 2011 | 554 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 983 | 0.040 |
Why?
| | Schools, Medical | 1 | 2019 | 139 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1012 | 0.040 |
Why?
| | Feedback | 1 | 2018 | 153 | 0.040 |
Why?
| | Models, Educational | 1 | 2017 | 99 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2018 | 162 | 0.040 |
Why?
| | Medication Adherence | 1 | 2022 | 556 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2020 | 545 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2021 | 788 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 5116 | 0.040 |
Why?
| | Mice | 3 | 2008 | 15520 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2020 | 635 | 0.040 |
Why?
| | Focus Groups | 1 | 2018 | 387 | 0.030 |
Why?
| | Infant, Newborn | 3 | 2012 | 5255 | 0.030 |
Why?
| | Educational Measurement | 1 | 2018 | 289 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1901 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 278 | 0.030 |
Why?
| | Toll-Like Receptors | 2 | 2005 | 167 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 2995 | 0.030 |
Why?
| | Biomedical Research | 1 | 2019 | 612 | 0.030 |
Why?
| | Body Mass Index | 1 | 2020 | 2092 | 0.030 |
Why?
| | Sex Factors | 1 | 2018 | 1781 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2017 | 648 | 0.030 |
Why?
| | Signal Transduction | 1 | 2005 | 4709 | 0.030 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2011 | 22 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2011 | 33 | 0.030 |
Why?
| | Acids, Carbocyclic | 1 | 2011 | 1 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4196 | 0.020 |
Why?
| | Decision Trees | 1 | 2011 | 83 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2011 | 66 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 143 | 0.020 |
Why?
| | Quality-Adjusted Life Years | 1 | 2011 | 103 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 658 | 0.020 |
Why?
| | Cost of Illness | 1 | 2012 | 258 | 0.020 |
Why?
| | Diarrhea | 1 | 2011 | 181 | 0.020 |
Why?
| | Streptococcus pneumoniae | 1 | 2011 | 141 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2011 | 324 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 513 | 0.020 |
Why?
| | Mass Vaccination | 1 | 2009 | 17 | 0.020 |
Why?
| | Calibration | 1 | 2010 | 135 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 380 | 0.020 |
Why?
| | Attitude to Health | 1 | 2013 | 410 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 12978 | 0.020 |
Why?
| | Travel | 1 | 2010 | 116 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1185 | 0.020 |
Why?
| | Immunization Programs | 1 | 2011 | 206 | 0.020 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 126 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2011 | 300 | 0.020 |
Why?
| | Workplace | 1 | 2009 | 222 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 299 | 0.020 |
Why?
| | Occupational Health | 1 | 2009 | 172 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2011 | 364 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1129 | 0.020 |
Why?
| | Pilot Projects | 1 | 2011 | 1419 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2010 | 405 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1882 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2008 | 749 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 516 | 0.020 |
Why?
| | Gram-Negative Bacteria | 1 | 2005 | 70 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 250 | 0.020 |
Why?
| | Incidence | 1 | 2011 | 2424 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2005 | 95 | 0.020 |
Why?
| | DNA | 1 | 2011 | 1388 | 0.020 |
Why?
| | Growth | 1 | 2004 | 58 | 0.020 |
Why?
| | Sugar Acids | 1 | 2004 | 5 | 0.020 |
Why?
| | U937 Cells | 1 | 2004 | 26 | 0.020 |
Why?
| | Respiratory Burst | 1 | 2004 | 31 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2017 | 9342 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2004 | 156 | 0.010 |
Why?
| | Vaccination | 1 | 2011 | 1222 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2004 | 127 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1715 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 4552 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 522 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 394 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2008 | 3171 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2005 | 892 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 6412 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 1900 | 0.010 |
Why?
|
|
Zimmer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|